CHRIS A. RALLIS - 26 Mar 2024 Form 4 Insider Report for FENNEC PHARMACEUTICALS INC. (FENC)

Role
Director
Signature
/s/ Chris A. Rallis
Issuer symbol
FENC
Transactions as of
26 Mar 2024
Net transactions value
-$23,191
Form type
4
Filing time
27 Mar 2024, 16:24:10 UTC
Previous filing
28 Dec 2023
Next filing
15 Apr 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FENC Common Shares Sale $23,191 -2,114 -4.9% $10.97 40,920 26 Mar 2024 Direct F1
transaction FENC Common Shares Options Exercise $10,000 +4,329 +11% $2.31 45,249 26 Mar 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FENC Common Shares Options Exercise $10,000 -4,329 -2.3% $2.31 182,983 26 Mar 2024 Options 4,239 $2.31 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares sold to satisfy tax obligation on option exercise.
F2 Shares acquired through the exercise of an option pusuant to a 10b5-1 plan adopted on August 17, 2023.
F3 Represents options exercised pursuant to a 10b5-1 plan adopted on August 17, 2023.